Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 27.8
(3.15%)
SEK 27.8
(3.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -179.66 Million SEK | -37.92% |
| 2022 | -130.26 Million SEK | -34.71% |
| 2021 | -96.7 Million SEK | -84.89% |
| 2020 | -52.3 Million SEK | -14.11% |
| 2019 | -45.83 Million SEK | -98.45% |
| 2018 | -23.09 Million SEK | -75.01% |
| 2017 | -13.19 Million SEK | -222.15% |
| 2016 | -4.09 Million SEK | 66.12% |
| 2015 | -12.09 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -67.74 Million SEK | -24.3% |
| 2024 Q2 | -53.58 Million SEK | 20.9% |
| 2023 FY | -179.66 Million SEK | -37.92% |
| 2023 Q3 | -38.94 Million SEK | 24.24% |
| 2023 Q1 | -34.26 Million SEK | 37.53% |
| 2023 Q2 | -51.4 Million SEK | -50.01% |
| 2023 Q4 | -54.49 Million SEK | -39.94% |
| 2022 FY | -130.26 Million SEK | -34.71% |
| 2022 Q4 | -54.85 Million SEK | -93.77% |
| 2022 Q2 | -28.52 Million SEK | -53.45% |
| 2022 Q3 | -28.3 Million SEK | 0.74% |
| 2022 Q1 | -18.58 Million SEK | 64.22% |
| 2021 Q1 | -13.91 Million SEK | 7.08% |
| 2021 FY | -96.7 Million SEK | -84.89% |
| 2021 Q2 | -16.95 Million SEK | -21.85% |
| 2021 Q3 | -13.89 Million SEK | 18.06% |
| 2021 Q4 | -51.94 Million SEK | -273.97% |
| 2020 Q4 | -14.97 Million SEK | -29.52% |
| 2020 FY | -52.3 Million SEK | -14.11% |
| 2020 Q3 | -11.56 Million SEK | 24.67% |
| 2020 Q2 | -15.34 Million SEK | -45.71% |
| 2020 Q1 | -10.53 Million SEK | 32.63% |
| 2019 Q2 | -11.05 Million SEK | -29.98% |
| 2019 Q1 | -8.5 Million SEK | 19.76% |
| 2019 Q3 | -10.58 Million SEK | 4.24% |
| 2019 FY | -45.83 Million SEK | -98.45% |
| 2019 Q4 | -15.63 Million SEK | -47.72% |
| 2018 Q4 | -10.59 Million SEK | -157.46% |
| 2018 Q1 | -1.59 Million SEK | 66.12% |
| 2018 FY | -23.09 Million SEK | -75.01% |
| 2018 Q2 | -6.78 Million SEK | -325.38% |
| 2018 Q3 | -4.11 Million SEK | 39.37% |
| 2017 Q4 | -4.71 Million SEK | -66.13% |
| 2017 Q1 | -6.33 Million SEK | -164.77% |
| 2017 Q2 | 681 Thousand SEK | 110.75% |
| 2017 FY | -13.19 Million SEK | -222.15% |
| 2017 Q3 | -2.83 Million SEK | -516.45% |
| 2016 Q1 | -3.57 Million SEK | 0.0% |
| 2016 FY | -4.09 Million SEK | 66.12% |
| 2016 Q3 | -6.72 Million SEK | -88.11% |
| 2016 Q4 | 9.77 Million SEK | 245.39% |
| 2016 Q2 | -3.57 Million SEK | 0.0% |
| 2015 FY | -12.09 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 61.46% |
| Camurus AB (publ) | 431.44 Million SEK | 141.643% |
| Mendus AB (publ) | -101.61 Million SEK | -76.805% |
| Lipum AB (publ) | -37.17 Million SEK | -383.262% |
| NextCell Pharma AB | -41.95 Million SEK | -328.188% |
| Simris Alg AB (publ) | -37.3 Million SEK | -381.616% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -995.666% |
| Active Biotech AB (publ) | -45.8 Million SEK | -292.286% |
| Amniotics AB (publ) | -30.87 Million SEK | -482.012% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1300.585% |
| BioArctic AB (publ) | 229.24 Million SEK | 178.372% |
| Cantargia AB (publ) | -280.02 Million SEK | 35.839% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -751.866% |
| CombiGene AB (publ) | -35.66 Million SEK | -403.757% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -18.319% |
| Genovis AB (publ.) | 61.5 Million SEK | 392.141% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -58.544% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -384.656% |
| Intervacc AB (publ) | -102.85 Million SEK | -74.685% |
| Kancera AB (publ) | -64.88 Million SEK | -176.884% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 3435.815% |
| LIDDS AB (publ) | -40.2 Million SEK | -346.866% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1381.423% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1576.432% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1029.839% |
| Saniona AB (publ) | -95.81 Million SEK | -87.524% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 42.218% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 53.715% |
| Xintela AB (publ) | -54.08 Million SEK | -232.206% |
| Ziccum AB (publ) | -21.41 Million SEK | -739.095% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -903.895% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 27.724% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -40919.863% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -987.375% |
| Corline Biomedical AB | -1.8 Million SEK | -9831.841% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -1.028% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -216.198% |
| Aptahem AB (publ) | -11.11 Million SEK | -1516.747% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -45.99% |
| Fluicell AB (publ) | -26.55 Million SEK | -576.61% |
| Biovica International AB (publ) | -124.82 Million SEK | -43.937% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -325.519% |
| AcouSort AB (publ) | -17.08 Million SEK | -951.361% |
| Abliva AB (publ) | -95.5 Million SEK | -88.115% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 45.039% |
| 2cureX AB (publ) | -32.51 Million SEK | -452.516% |
| I-Tech AB | 20.2 Million SEK | 989.309% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 78.398% |
| Cyxone AB (publ) | -22.98 Million SEK | -681.535% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -96.57% |
| Biosergen AB | -27.03 Million SEK | -564.523% |
| Nanologica AB (publ) | -75.15 Million SEK | -139.056% |
| SynAct Pharma AB | -215.81 Million SEK | 16.748% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -307.834% |
| BioInvent International AB (publ) | -330.3 Million SEK | 45.606% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -656.907% |
| Alzinova AB (publ) | -16.48 Million SEK | -990.212% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 27.877% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1709.334% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -64.398% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -1438.508% |